The NVPO is offering a cooperative agreement program for exploratory vaccine safety research projects that can be completed within one year. This grant aims to strengthen the U.S. vaccine safety enterprise by funding collaborative interdisciplinary proposals. Previous projects funded by NVPO included studies on fever post-vaccination in babies and interventions to reduce vaccine injection pain. NVPO’s scientific staff will provide guidance, support, and frequent communications throughout the research process. This grant opportunity is part of the NVPO-led Immunization Safety Task Force’s efforts to enhance the Vaccine Safety System outlined in the National Vaccine Plan. Closing date for applications is March 27, 2017.
Opportunity ID: 288893
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | NV-VSR-17-001 |
| Funding Opportunity Title: | FY17 Announcement of Anticipated Availability of Funds for Safety Research of Currently Recommended Immunizations in the United States and Other Vaccine Prototypes |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 93.344 — Research, Monitoring and Outcomes Definitions for Vaccine Safety |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 27, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Mar 27, 2017 No Explanation |
| Current Closing Date for Applications: | Mar 27, 2017 No Explanation |
| Archive Date: | Apr 26, 2017 |
| Estimated Total Program Funding: | $750,000 |
| Award Ceiling: | $400,000 |
| Award Floor: | $200,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligible Applicants The applicable authority, section 1702(a) of the Public Health Service Act, has no restriction on eligible entities. Eligible applicant examples include: • Non-profit with 501C3 IRS status (other than institution of higher education) • Non-profit without 501C3 IRS status (other than institution of higher education) • For-profit organizations (other than small business) • Small, minority, and women-owned businesses • Universities • Colleges • Research institutions • Hospitals • Community-based organizations • Faith-based organizations • Federally recognized or state-recognized American Indian/Alaska Native tribal governments • American Indian/Alaska native tribally designated organizations • Alaska Native health corporations • Urban Indian health organizations • Tribal epidemiology centers • State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) • Political subdivisions of States (in consultation with States) • Public (including city, county, regional, and State government) organizations. • International institution or organization including, but not limited to, academia and non-profit |
Additional Information
| Agency Name: | Office of the Assistant Secretary for Health |
| Description: | The National Vaccine Program Office (NVPO) provides strategic direction for the coordination of the vaccine and immunization enterprise through the implementation of the National Vaccine Plan (NVP). With respect to Goal 2: Enhance the Vaccine Safety System of the NVP, NVPO specifically provides guidance and coordination for vaccine safety-related activities through the NVPO-led Immunization Safety Task Force (ISTF). The ISTF was formed in 2009 to better coordinate all federal entities engaged in U.S. vaccine safety activities and includes subject matter experts from HHS (the Biomedical Advanced Research and Development Authority (BARDA), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Indian Health Service (IHS), the National Institutes of Health (NIH), and the Health Resources and Services Administration (HRSA)), as well as the Veterans Administration and the Department of Defense. In this capacity, the ISTF is able to identify scientific and programmatic opportunities to improve vaccine safety monitoring and research. NVPOs cooperative agreement program is a mechanism to collaborate with one or more institutions or organizations, including state and local public health departments and HHS Regional Offices, to conduct research that will strengthen the current U.S. vaccine safety enterprise. This program encourages collaborative interdisciplinary proposals to maximize the results and impact of the research project. This NVPOs cooperative agreement program (NV-VSR-17-001) is one of several federally-funded opportunities for vaccine safety research, including PA-15-312/ PA-15-313, under the title âÂÂResearch to Advance Vaccine Safety (R01/R21)â funded by the NIH and the CDC. NV-VSR-17-001 is intended to offer support for exploratory and programmatic vaccine safety research, as articulated above, that can be completed within one year. Vaccine safety projects previously awarded by NVPO included two cooperative agreements on the topics of vaccine safety research and prevention of adverse events after vaccine administration. The first project analyzed fever after vaccination in babies who received their first pertussis immunization and had been born to vaccinated mothers compared to those who had been born to unvaccinated mothers. The second project focused on developing an evidence-base intervention to reduce pain or the perception of pain from a vaccine injection. NVPOs scientific staff will have substantial involvement in carrying out the activity proposed by the award that is above and beyond the normal stewardship role in awards, as described below: ⢠Provide guidance and support in the design and development of the research project; ⢠Serve as a resource to provide scientific/programmatic support during the conduct of the research by participating in the design of the activities, and assisting with access to vaccine safety stakeholders; ⢠Have frequent communications with the principal investigator (PI) and study team to discuss progress of research, and determine next steps; and ⢠Participate in the preparation of publications and public presentations of the data obtained under this cooperative agreement. |
| Link to Additional Information: | FY17 Announcement of Anticipated Availability of Funds for Safety Research of Currently Recommended Immunizations in the United States and Other Vaccine Prototypes |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | Grants.gov Contact Center Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email: support@grants.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.344 | NV-VSR-17-001-058586 | FY17 Announcement of Anticipated Availability of Funds for Safety Research of Currently Recommended Immunizations in the United States and Other Vaccine Prototypes | PKG00230007 | Dec 27, 2016 | Mar 27, 2017 | View |
Package 1
Mandatory forms
288893 SF424_2_1-2.1.pdf
288893 Project-1.1.pdf
288893 Budget-1.1.pdf
288893 SF424B-1.1.pdf
288893 SF424A-1.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
